High-grade serous ovarian cancer
Prepared with OnCo (onco.cc/prep/high-grade-serous-ovarian-cancer/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
20 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example TP53 mutation, Germline and somatic BRCA1/2, HRD score, Folate receptor alpha, CA-125 for monitoring), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (first line), which of the standard options do you recommend and why?
- 6.Am I a candidate for Carboplatin, Paclitaxel / nab-paclitaxel, Bevacizumab, and what side effects should I expect?
- 7.For my situation (maintenance after first line), which of the standard options do you recommend and why?
- 8.Am I a candidate for Olaparib, Niraparib, and what side effects should I expect?
- 9.How do the results of SOLO-1 and PRIMA / ENGOT-OV26 apply to someone like me?
- 10.For my situation (platinum-sensitive relapse), which of the standard options do you recommend and why?
- 11.Am I a candidate for Rucaparib, Niraparib, and what side effects should I expect?
- 12.How do the results of DESKTOP III / ENGOT-ov20 apply to someone like me?
- 13.For my situation (platinum-resistant relapse), which of the standard options do you recommend and why?
- 14.Am I a candidate for Mirvetuximab soravtansine, Relacorilant, Bevacizumab, and what side effects should I expect?
- 15.For my situation (prevention in carriers), which of the standard options do you recommend and why?
- 16.Are there clinical trials I could join, for example of Mirvetuximab soravtansine, Relacorilant, Folate receptor alpha?
- 17.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 18.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 19.I read that “No screening test lowers mortality”. How does that affect my plan?
- 20.I read that “Homologous recombination proficient tumours gain little from PARP inhibitors”. How does that affect my plan?
The words I may hear
- Homologous recombination deficiency (HRD): A tumour that cannot properly repair double-strand DNA breaks, usually because of BRCA or related gene loss.
Tests and results to bring
Biomarker results to ask for: TP53 mutation (universal), Germline and somatic BRCA1/2, HRD score (Myriad myChoice or equivalent), Folate receptor alpha (mirvetuximab), CA-125 for monitoring, Platinum-free interval.
Scans and tests linked to this cancer: HRD genomic scar scores (GIS, LOH, HRDetect), RAD51 foci assay (functional HRD test).
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Prevention in carriers: Risk-reducing salpingo-oophorectomy around age 35 to 45 by gene; opportunistic salpingectomy at other pelvic surgery for everyone. (BRCA1 / BRCA2 (HRD), Risk-reducing and opportunistic salpingectomy)
- First line: Complete cytoreductive surgery, primary or after three cycles, with carboplatin-paclitaxel for six cycles; bevacizumab added in stage IV or residual disease. (Carboplatin, Paclitaxel / nab-paclitaxel, Bevacizumab, HIPEC / PIPAC (intraperitoneal chemotherapy))
- Platinum-sensitive relapse: Secondary cytoreduction in selected patients (DESKTOP III), platinum doublet, PARP inhibitor maintenance if not already used. (DESKTOP III / ENGOT-ov20, Rucaparib, Niraparib)
- Platinum-resistant relapse: Single-agent chemotherapy with or without bevacizumab; mirvetuximab soravtansine for folate receptor alpha-high tumours (MIRASOL); relacorilant with nab-paclitaxel in trials and early approvals. (Mirvetuximab soravtansine, Folate receptor alpha, Relacorilant, Bevacizumab)
- Maintenance after first line: Olaparib for BRCA-mutant tumours (SOLO-1), niraparib for all comers (PRIMA), olaparib plus bevacizumab for HRD-positive tumours (PAOLA-1). (Olaparib, Niraparib, SOLO-1, PRIMA / ENGOT-OV26, PAOLA-1 / ENGOT-ov25, Homologous recombination deficiency (HRD), BRCA1 / BRCA2 (HRD))
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.